Methoxphenidine (MXP) induced abnormalities: Addictive and schizophrenia‐related behaviours based on an imbalance of neurochemicals in the brain

Background and Purpose Methoxphenidine is a dissociative‐based novel psychoactive designer drug. Although fatal accidents from methoxphenidine abuse have been reported, recreational use of the drug continues. We aim to provide scientific supportfor legal regulation of recreational abuse of methoxphe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of pharmacology 2021-10, Vol.178 (19), p.3869-3887
Hauptverfasser: Hur, Kwang‐Hyun, Kim, Seong‐Eon, Ma, Shi‐Xun, Lee, Bo‐Ram, Ko, Yong‐Hyun, Seo, Jee‐Yeon, Kim, Seon‐Kyung, Kim, Young‐Jung, Sung, Su‐Jeong, Lee, Youyoung, Jung, Young Hoon, Lee, Yong‐Sup, Lee, Seok‐Yong, Jang, Choon‐Gon
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3887
container_issue 19
container_start_page 3869
container_title British journal of pharmacology
container_volume 178
creator Hur, Kwang‐Hyun
Kim, Seong‐Eon
Ma, Shi‐Xun
Lee, Bo‐Ram
Ko, Yong‐Hyun
Seo, Jee‐Yeon
Kim, Seon‐Kyung
Kim, Young‐Jung
Sung, Su‐Jeong
Lee, Youyoung
Jung, Young Hoon
Lee, Yong‐Sup
Lee, Seok‐Yong
Jang, Choon‐Gon
description Background and Purpose Methoxphenidine is a dissociative‐based novel psychoactive designer drug. Although fatal accidents from methoxphenidine abuse have been reported, recreational use of the drug continues. We aim to provide scientific supportfor legal regulation of recreational abuse of methoxphenidine by demonstrating its the pharmacological action. Experimental Approach Addictive potential of methoxphenidine was examined using intravenous self‐administration test with rats and conditioned place preference test with mice. Further, a series of behavioural tests (open field test, elevated plus maze test, novel object recognition test, social interaction test and tail suspension test) performed to assess whether methoxphenidine caused schizophrenia‐related symptoms in mice. Additionally, neurotransmitter enzyme‐linked immunosorbent assay and western blot were used to confirm methoxphenidine‐induced neurochemical changes in specific brain regions related to abnormal behaviours. Key Results Methoxphenidine caused addictive behaviours via reinforcing and rewarding effects. Consistently, methoxphenidine induced over‐activation of dopamine pathways in the nuclear accumbens, indicating activation of the brain reward circuit. Also, methoxphenidine caused all categories of schizophrenia‐related symptoms, including positive symptoms (hyperactivity, impulsivity), negative symptoms (anxiety, social withdrawal, depression) and cognitive impairment. Consistently, methoxphenidine led to the disruption of the hippocampal–prefrontal cortex pathway that is considered to be pathological involved in schizophrenia. Conclusions and Implications We demonastrate that methoxphenidine causes addictive and schizophrenia‐like behaviours and induces neurochemical changes in brain regions associated with these behaviours. We propose that methoxphenidine could be used in developing useful animal disease models and that it also requires legal restrictions on its recreational use.
doi_str_mv 10.1111/bph.15528
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2571619496</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2571619496</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3888-6a2557e986c7ddde30f3b0741781a9f013b1077b84000ce02bcf4a284b4a91173</originalsourceid><addsrcrecordid>eNp1kMtO3DAUhq2KqgyXRV-gssSmLDLYudnpDhAwSIyYBUjsIl9OFKPETu2EdrriERCPyJPUZabd9WyOdPyd_1gfQp8pmdNYJ3Jo57QoUv4BzWjOyqTION1BM0IISyjlfBfthfBISHxkxSe0m2UVZzxlM_S6hLF1P4cWrNHGAv66fFgdY2P1pEBjIa3zvejMaCB8w6daGzWaJ8DCahxUa365ofVxV7w9v3joxBiXJLTiybjJByxFiANnI49NL0UnrALsGmxh8k610BsluhDv4bEFLL0w9gB9bOIMDrd9H91fXtydL5Kb26vr89ObRGWc86QUaVEwqHipmNYaMtJkkrCcMk5F1RCaSUoYkzyPGhSQVKomFynPZS4qSlm2j442uYN33ycIY_0Y_2zjyTotGC1plVdlpI43lPIuBA9NPXjTC7-uKan_2K-j_frdfmS_bBMn2YP-R_7VHYGTDfDDdLD-f1J9tlpsIn8DroiQ2w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2571619496</pqid></control><display><type>article</type><title>Methoxphenidine (MXP) induced abnormalities: Addictive and schizophrenia‐related behaviours based on an imbalance of neurochemicals in the brain</title><source>Wiley Online Library Free Content</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Hur, Kwang‐Hyun ; Kim, Seong‐Eon ; Ma, Shi‐Xun ; Lee, Bo‐Ram ; Ko, Yong‐Hyun ; Seo, Jee‐Yeon ; Kim, Seon‐Kyung ; Kim, Young‐Jung ; Sung, Su‐Jeong ; Lee, Youyoung ; Jung, Young Hoon ; Lee, Yong‐Sup ; Lee, Seok‐Yong ; Jang, Choon‐Gon</creator><creatorcontrib>Hur, Kwang‐Hyun ; Kim, Seong‐Eon ; Ma, Shi‐Xun ; Lee, Bo‐Ram ; Ko, Yong‐Hyun ; Seo, Jee‐Yeon ; Kim, Seon‐Kyung ; Kim, Young‐Jung ; Sung, Su‐Jeong ; Lee, Youyoung ; Jung, Young Hoon ; Lee, Yong‐Sup ; Lee, Seok‐Yong ; Jang, Choon‐Gon</creatorcontrib><description>Background and Purpose Methoxphenidine is a dissociative‐based novel psychoactive designer drug. Although fatal accidents from methoxphenidine abuse have been reported, recreational use of the drug continues. We aim to provide scientific supportfor legal regulation of recreational abuse of methoxphenidine by demonstrating its the pharmacological action. Experimental Approach Addictive potential of methoxphenidine was examined using intravenous self‐administration test with rats and conditioned place preference test with mice. Further, a series of behavioural tests (open field test, elevated plus maze test, novel object recognition test, social interaction test and tail suspension test) performed to assess whether methoxphenidine caused schizophrenia‐related symptoms in mice. Additionally, neurotransmitter enzyme‐linked immunosorbent assay and western blot were used to confirm methoxphenidine‐induced neurochemical changes in specific brain regions related to abnormal behaviours. Key Results Methoxphenidine caused addictive behaviours via reinforcing and rewarding effects. Consistently, methoxphenidine induced over‐activation of dopamine pathways in the nuclear accumbens, indicating activation of the brain reward circuit. Also, methoxphenidine caused all categories of schizophrenia‐related symptoms, including positive symptoms (hyperactivity, impulsivity), negative symptoms (anxiety, social withdrawal, depression) and cognitive impairment. Consistently, methoxphenidine led to the disruption of the hippocampal–prefrontal cortex pathway that is considered to be pathological involved in schizophrenia. Conclusions and Implications We demonastrate that methoxphenidine causes addictive and schizophrenia‐like behaviours and induces neurochemical changes in brain regions associated with these behaviours. We propose that methoxphenidine could be used in developing useful animal disease models and that it also requires legal restrictions on its recreational use.</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1111/bph.15528</identifier><identifier>PMID: 33987827</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>addiction ; Addictive behaviors ; Animal diseases ; Animal models ; Brain ; Cognitive ability ; dissociative drug ; Emotional behavior ; Hippocampus ; Hyperactivity ; Impulsive behavior ; Intravenous administration ; Mental disorders ; methoxphenidine ; MXP ; NMDA receptor antagonist ; Nucleus accumbens ; Open-field behavior ; Pattern recognition ; Place preference conditioning ; Prefrontal cortex ; Reinforcement ; Schizophrenia ; Social interactions ; Withdrawal</subject><ispartof>British journal of pharmacology, 2021-10, Vol.178 (19), p.3869-3887</ispartof><rights>2021 The British Pharmacological Society</rights><rights>This article is protected by copyright. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3888-6a2557e986c7ddde30f3b0741781a9f013b1077b84000ce02bcf4a284b4a91173</citedby><cites>FETCH-LOGICAL-c3888-6a2557e986c7ddde30f3b0741781a9f013b1077b84000ce02bcf4a284b4a91173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbph.15528$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbph.15528$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33987827$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hur, Kwang‐Hyun</creatorcontrib><creatorcontrib>Kim, Seong‐Eon</creatorcontrib><creatorcontrib>Ma, Shi‐Xun</creatorcontrib><creatorcontrib>Lee, Bo‐Ram</creatorcontrib><creatorcontrib>Ko, Yong‐Hyun</creatorcontrib><creatorcontrib>Seo, Jee‐Yeon</creatorcontrib><creatorcontrib>Kim, Seon‐Kyung</creatorcontrib><creatorcontrib>Kim, Young‐Jung</creatorcontrib><creatorcontrib>Sung, Su‐Jeong</creatorcontrib><creatorcontrib>Lee, Youyoung</creatorcontrib><creatorcontrib>Jung, Young Hoon</creatorcontrib><creatorcontrib>Lee, Yong‐Sup</creatorcontrib><creatorcontrib>Lee, Seok‐Yong</creatorcontrib><creatorcontrib>Jang, Choon‐Gon</creatorcontrib><title>Methoxphenidine (MXP) induced abnormalities: Addictive and schizophrenia‐related behaviours based on an imbalance of neurochemicals in the brain</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>Background and Purpose Methoxphenidine is a dissociative‐based novel psychoactive designer drug. Although fatal accidents from methoxphenidine abuse have been reported, recreational use of the drug continues. We aim to provide scientific supportfor legal regulation of recreational abuse of methoxphenidine by demonstrating its the pharmacological action. Experimental Approach Addictive potential of methoxphenidine was examined using intravenous self‐administration test with rats and conditioned place preference test with mice. Further, a series of behavioural tests (open field test, elevated plus maze test, novel object recognition test, social interaction test and tail suspension test) performed to assess whether methoxphenidine caused schizophrenia‐related symptoms in mice. Additionally, neurotransmitter enzyme‐linked immunosorbent assay and western blot were used to confirm methoxphenidine‐induced neurochemical changes in specific brain regions related to abnormal behaviours. Key Results Methoxphenidine caused addictive behaviours via reinforcing and rewarding effects. Consistently, methoxphenidine induced over‐activation of dopamine pathways in the nuclear accumbens, indicating activation of the brain reward circuit. Also, methoxphenidine caused all categories of schizophrenia‐related symptoms, including positive symptoms (hyperactivity, impulsivity), negative symptoms (anxiety, social withdrawal, depression) and cognitive impairment. Consistently, methoxphenidine led to the disruption of the hippocampal–prefrontal cortex pathway that is considered to be pathological involved in schizophrenia. Conclusions and Implications We demonastrate that methoxphenidine causes addictive and schizophrenia‐like behaviours and induces neurochemical changes in brain regions associated with these behaviours. We propose that methoxphenidine could be used in developing useful animal disease models and that it also requires legal restrictions on its recreational use.</description><subject>addiction</subject><subject>Addictive behaviors</subject><subject>Animal diseases</subject><subject>Animal models</subject><subject>Brain</subject><subject>Cognitive ability</subject><subject>dissociative drug</subject><subject>Emotional behavior</subject><subject>Hippocampus</subject><subject>Hyperactivity</subject><subject>Impulsive behavior</subject><subject>Intravenous administration</subject><subject>Mental disorders</subject><subject>methoxphenidine</subject><subject>MXP</subject><subject>NMDA receptor antagonist</subject><subject>Nucleus accumbens</subject><subject>Open-field behavior</subject><subject>Pattern recognition</subject><subject>Place preference conditioning</subject><subject>Prefrontal cortex</subject><subject>Reinforcement</subject><subject>Schizophrenia</subject><subject>Social interactions</subject><subject>Withdrawal</subject><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kMtO3DAUhq2KqgyXRV-gssSmLDLYudnpDhAwSIyYBUjsIl9OFKPETu2EdrriERCPyJPUZabd9WyOdPyd_1gfQp8pmdNYJ3Jo57QoUv4BzWjOyqTION1BM0IISyjlfBfthfBISHxkxSe0m2UVZzxlM_S6hLF1P4cWrNHGAv66fFgdY2P1pEBjIa3zvejMaCB8w6daGzWaJ8DCahxUa365ofVxV7w9v3joxBiXJLTiybjJByxFiANnI49NL0UnrALsGmxh8k610BsluhDv4bEFLL0w9gB9bOIMDrd9H91fXtydL5Kb26vr89ObRGWc86QUaVEwqHipmNYaMtJkkrCcMk5F1RCaSUoYkzyPGhSQVKomFynPZS4qSlm2j442uYN33ycIY_0Y_2zjyTotGC1plVdlpI43lPIuBA9NPXjTC7-uKan_2K-j_frdfmS_bBMn2YP-R_7VHYGTDfDDdLD-f1J9tlpsIn8DroiQ2w</recordid><startdate>202110</startdate><enddate>202110</enddate><creator>Hur, Kwang‐Hyun</creator><creator>Kim, Seong‐Eon</creator><creator>Ma, Shi‐Xun</creator><creator>Lee, Bo‐Ram</creator><creator>Ko, Yong‐Hyun</creator><creator>Seo, Jee‐Yeon</creator><creator>Kim, Seon‐Kyung</creator><creator>Kim, Young‐Jung</creator><creator>Sung, Su‐Jeong</creator><creator>Lee, Youyoung</creator><creator>Jung, Young Hoon</creator><creator>Lee, Yong‐Sup</creator><creator>Lee, Seok‐Yong</creator><creator>Jang, Choon‐Gon</creator><general>Blackwell Publishing Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>202110</creationdate><title>Methoxphenidine (MXP) induced abnormalities: Addictive and schizophrenia‐related behaviours based on an imbalance of neurochemicals in the brain</title><author>Hur, Kwang‐Hyun ; Kim, Seong‐Eon ; Ma, Shi‐Xun ; Lee, Bo‐Ram ; Ko, Yong‐Hyun ; Seo, Jee‐Yeon ; Kim, Seon‐Kyung ; Kim, Young‐Jung ; Sung, Su‐Jeong ; Lee, Youyoung ; Jung, Young Hoon ; Lee, Yong‐Sup ; Lee, Seok‐Yong ; Jang, Choon‐Gon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3888-6a2557e986c7ddde30f3b0741781a9f013b1077b84000ce02bcf4a284b4a91173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>addiction</topic><topic>Addictive behaviors</topic><topic>Animal diseases</topic><topic>Animal models</topic><topic>Brain</topic><topic>Cognitive ability</topic><topic>dissociative drug</topic><topic>Emotional behavior</topic><topic>Hippocampus</topic><topic>Hyperactivity</topic><topic>Impulsive behavior</topic><topic>Intravenous administration</topic><topic>Mental disorders</topic><topic>methoxphenidine</topic><topic>MXP</topic><topic>NMDA receptor antagonist</topic><topic>Nucleus accumbens</topic><topic>Open-field behavior</topic><topic>Pattern recognition</topic><topic>Place preference conditioning</topic><topic>Prefrontal cortex</topic><topic>Reinforcement</topic><topic>Schizophrenia</topic><topic>Social interactions</topic><topic>Withdrawal</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hur, Kwang‐Hyun</creatorcontrib><creatorcontrib>Kim, Seong‐Eon</creatorcontrib><creatorcontrib>Ma, Shi‐Xun</creatorcontrib><creatorcontrib>Lee, Bo‐Ram</creatorcontrib><creatorcontrib>Ko, Yong‐Hyun</creatorcontrib><creatorcontrib>Seo, Jee‐Yeon</creatorcontrib><creatorcontrib>Kim, Seon‐Kyung</creatorcontrib><creatorcontrib>Kim, Young‐Jung</creatorcontrib><creatorcontrib>Sung, Su‐Jeong</creatorcontrib><creatorcontrib>Lee, Youyoung</creatorcontrib><creatorcontrib>Jung, Young Hoon</creatorcontrib><creatorcontrib>Lee, Yong‐Sup</creatorcontrib><creatorcontrib>Lee, Seok‐Yong</creatorcontrib><creatorcontrib>Jang, Choon‐Gon</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hur, Kwang‐Hyun</au><au>Kim, Seong‐Eon</au><au>Ma, Shi‐Xun</au><au>Lee, Bo‐Ram</au><au>Ko, Yong‐Hyun</au><au>Seo, Jee‐Yeon</au><au>Kim, Seon‐Kyung</au><au>Kim, Young‐Jung</au><au>Sung, Su‐Jeong</au><au>Lee, Youyoung</au><au>Jung, Young Hoon</au><au>Lee, Yong‐Sup</au><au>Lee, Seok‐Yong</au><au>Jang, Choon‐Gon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Methoxphenidine (MXP) induced abnormalities: Addictive and schizophrenia‐related behaviours based on an imbalance of neurochemicals in the brain</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>2021-10</date><risdate>2021</risdate><volume>178</volume><issue>19</issue><spage>3869</spage><epage>3887</epage><pages>3869-3887</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><abstract>Background and Purpose Methoxphenidine is a dissociative‐based novel psychoactive designer drug. Although fatal accidents from methoxphenidine abuse have been reported, recreational use of the drug continues. We aim to provide scientific supportfor legal regulation of recreational abuse of methoxphenidine by demonstrating its the pharmacological action. Experimental Approach Addictive potential of methoxphenidine was examined using intravenous self‐administration test with rats and conditioned place preference test with mice. Further, a series of behavioural tests (open field test, elevated plus maze test, novel object recognition test, social interaction test and tail suspension test) performed to assess whether methoxphenidine caused schizophrenia‐related symptoms in mice. Additionally, neurotransmitter enzyme‐linked immunosorbent assay and western blot were used to confirm methoxphenidine‐induced neurochemical changes in specific brain regions related to abnormal behaviours. Key Results Methoxphenidine caused addictive behaviours via reinforcing and rewarding effects. Consistently, methoxphenidine induced over‐activation of dopamine pathways in the nuclear accumbens, indicating activation of the brain reward circuit. Also, methoxphenidine caused all categories of schizophrenia‐related symptoms, including positive symptoms (hyperactivity, impulsivity), negative symptoms (anxiety, social withdrawal, depression) and cognitive impairment. Consistently, methoxphenidine led to the disruption of the hippocampal–prefrontal cortex pathway that is considered to be pathological involved in schizophrenia. Conclusions and Implications We demonastrate that methoxphenidine causes addictive and schizophrenia‐like behaviours and induces neurochemical changes in brain regions associated with these behaviours. We propose that methoxphenidine could be used in developing useful animal disease models and that it also requires legal restrictions on its recreational use.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>33987827</pmid><doi>10.1111/bph.15528</doi><tpages>19</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1188
ispartof British journal of pharmacology, 2021-10, Vol.178 (19), p.3869-3887
issn 0007-1188
1476-5381
language eng
recordid cdi_proquest_journals_2571619496
source Wiley Online Library Free Content; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects addiction
Addictive behaviors
Animal diseases
Animal models
Brain
Cognitive ability
dissociative drug
Emotional behavior
Hippocampus
Hyperactivity
Impulsive behavior
Intravenous administration
Mental disorders
methoxphenidine
MXP
NMDA receptor antagonist
Nucleus accumbens
Open-field behavior
Pattern recognition
Place preference conditioning
Prefrontal cortex
Reinforcement
Schizophrenia
Social interactions
Withdrawal
title Methoxphenidine (MXP) induced abnormalities: Addictive and schizophrenia‐related behaviours based on an imbalance of neurochemicals in the brain
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T13%3A38%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Methoxphenidine%20(MXP)%20induced%20abnormalities:%20Addictive%20and%20schizophrenia%E2%80%90related%20behaviours%20based%20on%20an%20imbalance%20of%20neurochemicals%20in%20the%20brain&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Hur,%20Kwang%E2%80%90Hyun&rft.date=2021-10&rft.volume=178&rft.issue=19&rft.spage=3869&rft.epage=3887&rft.pages=3869-3887&rft.issn=0007-1188&rft.eissn=1476-5381&rft_id=info:doi/10.1111/bph.15528&rft_dat=%3Cproquest_cross%3E2571619496%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2571619496&rft_id=info:pmid/33987827&rfr_iscdi=true